Nano Dimension has announced a strategic partnership with Infinite Epigenetics, aimed at creating a publicly traded company focused on AI-driven preventive health and diagnostics. This collaboration follows a comprehensive review of potential opportunities in the healthcare sector, ultimately identifying Infinite Epigenetics as the most promising candidate for long-term value creation.
The proposed merger will leverage Nano Dimension's financial resources and Nasdaq listing to tap into the burgeoning healthcare AI market. Infinite Epigenetics is positioned to capitalize on the U.S. clinical diagnostics market, which exceeds $90 billion, by utilizing its extensive epigenetic dataset and proprietary AI platform. This platform aims to provide early warnings for disease risks, focusing initially on chronic conditions like cardiovascular disease and Type 2 diabetes, which affect billions globally.
Infinite Epigenetics, co-founded by notable figures in the field, has already established revenue-generating operations through its subsidiaries, TruDiagnostic and Tally Health, having collected over 120,000 epigenetic samples since 2020. The merger is expected to allow Nano Dimension shareholders to retain significant ownership in the combined entity, which will operate under the Infinite Epigenetics name and is projected to have over $400 million in cash post-transaction.
This strategic move underscores the increasing importance of integrating AI with biological data in healthcare, potentially transforming diagnostic capabilities and patient outcomes. The emphasis on early detection and prevention aligns with broader trends in healthcare aimed at reducing costs and improving quality of care, positioning Infinite Epigenetics as a key player in this evolving landscape.